Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. https://doi.org/10.3322/caac.21708. (e-pub ahead of print 20220112).

Article  PubMed  Google Scholar 

Cronin KA, Scott S, Firth AU, Sung H, Henley SJ, Sherman RL, et al. Annual report to the nation on the status of cancer, part 1: national cancer statistics. Cancer. 2022. https://doi.org/10.1002/cncr.34479. (e-pub ahead of print 20221027).

Article  PubMed  Google Scholar 

Dotan E, Walter LC, Browner IS, Clifton K, Cohen HJ, Extermann M, et al. NCCN Guidelines(R) insights: older adult oncology, Version 1.2021. J Natl Compr Canc Netw. 2021;19(9):1006–19. https://doi.org/10.6004/jnccn.2021.0043. (e-pub ahead of print 20210920).

Article  PubMed  Google Scholar 

Snowden JA, Sanchez-Ortega I, Corbacioglu S, Basak GW, Chabannon C, de la Camara R, et al. Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transplant. 2022;57(8):1217–39. https://doi.org/10.1038/s41409-022-01691-w. (e-pub ahead of print 20220519).

Article  PubMed  PubMed Central  Google Scholar 

Kanate AS, Majhail NS, Savani BN, Bredeson C, Champlin RE, Crawford S, et al. Indications for hematopoietic cell transplantation and immune effector cell therapy: guidelines from the American Society for transplantation and cellular therapy. Biol Blood Marrow Transplant. 2020;26(7):1247–56. https://doi.org/10.1016/j.bbmt.2020.03.002. (e-pub ahead of print 20200309).

Article  CAS  PubMed  Google Scholar 

Granot N, Storb R. History of hematopoietic cell transplantation: challenges and progress. Haematologica. 2020;105(12):2716–29. https://doi.org/10.3324/haematol.2019.245688. (e-pub ahead of print 20201201).

Article  PubMed  PubMed Central  Google Scholar 

Bacher U, Klyuchnikov E, Le-Rademacher J, Carreras J, Armand P, Bishop MR, et al. Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity? Blood. 2012;120(20):4256–62. https://doi.org/10.1182/blood-2012-06-436725.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Auletta JJ, Kou J, Chen M, Bolon Y, Broglie L, Bupp C, et al. Real-world data showing trends and outcomes by race and ethnicity in allogeneic hematopoietic cell transplantation: a report from the center for international blood and marrow transplant research. Transplant Cell Ther. 2023;29(6):346.e1–346.e10. https://doi.org/10.1016/j.jtct.2023.03.007

Chabannon C, Kuball J, Bondanza A, Dazzi F, Pedrazzoli P, Toubert, A et al. Hematopoietic stem cell transplantation in its 60s: a platform for cellular therapies. Sci Transl Med. 2018;10(436). https://doi.org/10.1126/scitranslmed.aap9630

Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354(17):1813–26. https://doi.org/10.1056/NEJMra052638.

Article  CAS  PubMed  Google Scholar 

Lin RJ, Artz AS. Allogeneic hematopoietic cell transplantation for older patients. Hematol Am Soc Hematol Educ Program. 2021;2021(1):254–63. https://doi.org/10.1182/hematology.2021000257.

Article  Google Scholar 

Muffly L, Pasquini MC, Martens M, Brazauskas R, Zhu X, Adekola K, et al. Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. Blood. 2017;130(9):1156–64. https://doi.org/10.1182/blood-2017-03-772368. (e-pub ahead of print 20170703).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rashidi A, Ebadi M, Colditz GA, DiPersio JF. Outcomes of allogeneic stem cell transplantation in elderly patients with acute myeloid leukemia: a systematic review and meta-analysis. Biol Blood Marrow Transplant. 2016;22(4):651–7. https://doi.org/10.1016/j.bbmt.2015.10.019. (e-pub ahead of print 20151031).

Article  PubMed  Google Scholar 

Sorror ML, Sandmaier BM, Storer BE, Franke GN, Laport GG, Chauncey TR, et al. Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. JAMA. 2011;306(17):1874–83. https://doi.org/10.1001/jama.2011.1558.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maakaron JE, Zhang MJ, Chen K, Abhyankar S, Bhatt VR, Chhabra S, et al. Age is no barrier for adults undergoing HCT for AML in CR1: contemporary CIBMTR analysis. Bone Marrow Transplant. 2022;57(6):911–7. https://doi.org/10.1038/s41409-022-01650-5. e-pub ahead of print 20220402. A comprehensive CIBMTR registry analysis of the impact of age on alloHCT outcomes for AML in CR1 in the modern era.

Article  PubMed  PubMed Central  Google Scholar 

Atallah E, Logan B, Chen M, Cutler C, Deeg J, Jacoby M, et al. Comparison of patient age groups in transplantation for myelodysplastic syndrome: the medicare coverage with evidence development study. JAMA Oncol. 2020;6(4):486–93. https://doi.org/10.1001/jamaoncol.2019.5140. A comprehensive CIBMTR registry analysis of the impact of age on alloHCT outcomes for MDS in the modern era.

Article  PubMed  Google Scholar 

Ringden O, Boumendil A, Labopin M, Canaani J, Beelen D, Ehninger G, et al. Outcome of allogeneic hematopoietic stem cell transplantation in patients age >69 years with acute myelogenous leukemia: on behalf of the acute leukemia working party of the european society for blood and marrow transplantation. Biol Blood Marrow Transplant. 2019;25(10):1975–83. https://doi.org/10.1016/j.bbmt.2019.05.037. (e-pub ahead of print 20190607).

Article  PubMed  Google Scholar 

Dahi PB, Lee J, Devlin SM, Ruiz J, Maloy M, Rondon-Clavo C, et al. Toxicities of high-dose chemotherapy and autologous hematopoietic cell transplantation in older patients with lymphoma. Blood Adv. 2021;5(12):2608–18. https://doi.org/10.1182/bloodadvances.2020004167.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chihara D, Izutsu K, Kondo E, Sakai R, Mizuta S, Yokoyama K, et al. High-dose chemotherapy with autologous stem cell transplantation for elderly patients with relapsed/refractory diffuse large B cell lymphoma: a nationwide retrospective study. Biol Blood Marrow Transplant. 2014;20(5):684–9. https://doi.org/10.1016/j.bbmt.2014.01.025. (e-pub ahead of print 20140131).

Article  CAS  PubMed  Google Scholar 

Dahi PB, Tamari R, Devlin SM, Maloy M, Bhatt V, Scordo M, et al. Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2014;20(12):2004–9. https://doi.org/10.1016/j.bbmt.2014.08.019. (e-pub ahead of print 20140828).

Article  PubMed  PubMed Central  Google Scholar 

Lin RJ, Lobaugh SM, Pennisi M, Chan HT, Batlevi Y, Ruiz JD, et al. Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed/refractory large B-cell lymphoma. Haematologica. 2021;106(1):255–8. https://doi.org/10.3324/haematol.2019.243246. (e-pub ahead of print 20210101).

Article  PubMed  Google Scholar 

Neelapu SS, Jacobson CA, Oluwole OO, Munoz J, Deol A, Miklos DB, et al. Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2020;135(23):2106–9. https://doi.org/10.1182/blood.2019004162. Outcomes of CAR T therapy in older versus younger patients from ZUMA-1 trial.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hurria A, Naylor M, Cohen HJ. Improving the quality of cancer care in an aging population: recommendations from an IOM report. JAMA. 2013;310(17):1795–6. https://doi.org/10.1001/jama.2013.280416.

Article  CAS  PubMed  Google Scholar 

Mohile SG, Dale W, Somerfield MR, Schonberg MA, Boyd CM, Burhenn PS, et al. Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO Guideline for geriatric oncology. J Clin Oncol. 2018;36(22):2326–47. https://doi.org/10.1200/JCO.2018.78.8687. (e-pub ahead of print 20180521).

Article  PubMed  PubMed Central  Google Scholar 

Wildiers H, Heeren P, Puts M, Topinkova E, Janssen-Heijnen ML, Extermann M, et al. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol. 2014;32(24):2595–603. https://doi.org/10.1200/JCO.2013.54.8347.

Article  PubMed  PubMed Central  Google Scholar 

DuMontier C, Loh KP, Bain PA, Silliman RA, Hshieh T, Abel GA, et al. Defining undertreatment and overtreatment in older adults with cancer: a scoping literature review. J Clin Oncol. 2020;38(22):2558–69. https://doi.org/10.1200/JCO.19.02809. e-pub ahead of print 20200406. A conceptual understanding of how geriatric assessment and management could improve modern cancer care.

Article  PubMed  PubMed Central  Google Scholar 

Flannelly C, Tan BE, Tan JL, McHugh CM, Sanapala C, Lagu T, et al. Barriers to hematopoietic cell transplantation for adults in the united states: a systematic review with a focus on age. Biol Blood Marrow Transplant. 2020;26(12):2335–45. https://doi.org/10.1016/j.bbmt.2020.09.013. >e-pub ahead of print 20200920. Chronologic age impacts on alloHCT referrals for older patients.

Article  PubMed  PubMed Central  Google Scholar 

Meyer C, Mau LW, Murphy EA, Denzen EM, Hayes E, Haven D, et al. Addressing knowledge gaps in acute myeloid leukemia to improve referral for hematopoietic cell transplantation consultation. J Natl Compr Canc Netw. 2019;17(12):1473–81. https://doi.org/10.6004/jnccn.2019.7327.

Article  PubMed  Google Scholar 

Appelbaum FR. Effectiveness of allogeneic hematopoietic cell transplantation for older patients with acute myeloid leukemia. Best Pract Res Clin Haematol. 2021;34(4):101320. https://doi.org/10.1016/j.beha.2021.101320. (e-pub ahead of print 20211022).

Article  CAS  PubMed  Google Scholar 

Vasu S, Kohlschmidt J, Mrozek K, Eisfeld AK, Nicolet D, Sterling LJ, et al. Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission. Blood Adv. 2018;2(13):1645–50. https://doi.org/10.1182/bloodadvances.2017015222. (e-pub ahead of print 2018/07/12).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pulte D, Jansen L, Castro FA, Brenner H. Changes in the survival of older patients with hematologic malignancies in the early 21st century. Cancer. 2016;122(13):2031–40. https://doi.org/10.1002/cncr.30003. (e-pub ahead of print 2016/05/11).

Article  PubMed  Google Scholar 

Ustun C, Le-Rademacher J, Wang HL, Othus M, Sun Z, Major B, et al. Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60–75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study. Leukemia. 2019;33(11):2599–609. https://doi.org/10.1038/s41375-019-0477-x. e-pub ahead of print 20190509. A non-randomized, but elegant analysis that demonstrated that older patients with AML in CR1 could benefit from alloHCT, albeit with heightened early mortality.

Article  CAS  PubMed  PubMed Central  Google Scholar